Part 1 Throughout the 1990s, stem-cell transplantation provided a possible cure for CML, but its use declined as tyrosine kinase inhibitors (TKIs) became available starting in 2001. Medications were highly effective in controlling CML, could be taken by most people, and were generally
Part 1 A CML therapy that emerged in the 1980s was stem-cell transplantation (SCT) (Thomas and colleagues. Ann Intern Med 1986;104:155-163). The idea was that leukemia originated in the bone marrow, so destroying the bone marrow and replacing it with new cells might cure the disease t
Life with chronic myelogenous leukemia changed a decade ago with what has been called the TKI revolution. The tyrosine kinase inhibitor (TKI) medications changed not only how CML is treated, but people’s expectations of what can be achieved.
In part 1 we looked at how a person’s response to TKI treatment is assessed and the importance of reaching key milestones. In Part 2 we looked at how a faster, deeper molecular response can translate to better outcomes.
While these standards were being developed, new laboratory techniques were enabling even more sensitive PCR testing for BCR-ABL transcripts. This opened up a new world beyond MMR – to a 4-log reduction, a 4.5-log reduction, and even a 5-log reduction.